참고문헌 (22)

1. Michaud CM, Murray CJ, Bloom BR. Burden of disease--implications for future research. Jama 2001;285:535-9. 

   상세보기

2. Paes BA, Mitchell I, Banerji A, Lanctot KL, Langley JM. A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice. Can Respir J 2011;18:e10-9. 

   

3. Korea Centers for Disease Control and Prevention. The prevalence of the respiratory viruses in the patients with acute respiratory infections, 2012. Public Health Weekly Report 2013;6:6. 

4. Frogel MP, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis. J Manag Care Pharm 2010;16:46-58. 

   상세보기

5. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997; 176:1215-24. 

   상세보기

6. Romero JR. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Pediatr Infect Dis J 2003;22:S46-54. 

7. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-7. 

   상세보기

8. The Korean Pediatric Society. [Immunoprophylaxis for Respiratory Syncytial Virus]. In: Lee HJ, ed. Immunization Guideline. 7th ed. Seoul: The Korean Pediatric Society; 2012: 231-3. 

9. Panozzo CA, Fowlkes AL, Anderson LJ. Variation in timing of respiratory syncytial virus outbreaks: lessons from national surveillance. Pediatr Infect Dis J 2007;26:S41-5. 

   상세보기

10. Mullins JA, Lamonte AC, Bresee JS, Anderson LJ. Substantial variability in community respiratory syncytial virus season timing. Pediatr Infect Dis J 2003;22:857-62. 

    상세보기

11. Respiratory syncytial virus--United States, July 2007-June 2011. MMWR Morb Mortal Wkly Rep 2011;60:1203-6. 

12. McGuiness CB, Boron ML, Saunders B, Edelman L, Kumar VR, Rabon-Stith KM. Respiratory syncytial virus surveillance in the United States, 2007-2012: results from a national surveillance system. Pediatr Infect Dis J 2014;33:589-94. 

    상세보기

13. Tatochenko V, Uchaikin V, Gorelov A, Gudkov K, Campbell A, Schulz G, et al. Epidemiology of respiratory syncytial virus in children $\leq$ 2 years of age hospitalized with lower respiratory tract infections in the Russian Federation: a prospective, multicenter study. Clin Epidemiol 2010;2:221-7. 

14. Fjaerli HO, Farstad T, Bratlid D. Hospitalisations for respiratory syncytial virus bronchiolitis in Akershus, Norway, 1993-2000: a population-based retrospective study. BMC Pediatr 2004;4:25. 

    상세보기

15. Hsu CH, Lin CY, Chi H, Chang JH, Hung HY, Kao HA, et al. Prolonged seasonality of respiratory syncytial virus infection among preterm infants in a subtropical climate. PLoS One 2014;9:e110166. 

    상세보기

16. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Pediatrics 1998;102:1211-6. 

    상세보기

17. Lambert M. AAP issues updated guidance on palivizumab prophylaxis for RSV infection. Am Fam Physician 2014;90: 867-8. 

    상세보기

18. Subramanian KN, Weisman LE, Rhodes T, Ariagno R, Sanchez PJ, Steichen J, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J 1998;17:110-5. 

    상세보기

19. Weinberger DM, Warren JL, Steiner CA, Charu V, Viboud C, Pitzer VE. Reduced-dose schedule of prophylaxis based on local data provides near-optimal protection against respiratory syncytial virus. Clin Infect Dis 2015;61:506-14. 

    상세보기

20. Weigl JA, Puppe W, Schmitt HJ. Seasonality of respiratory syncytial virus-positive hospitalizations in children in Kiel, Germany, over a 7-year period. Infection 2002;30:186-92. 

    상세보기

21. Korea Centers for Disease Control and Prevention. Weakly occurrence of acute respiratory tract infection with 8 respiratory viruses in Korea patients. Available from: http://www.cdc.go.kr/kcdchome. 

22. Park KH, Shin JH, Lee EH, Seo WH, Kim YK, Song DJ, et al. Seasonal variations of respiratory syncytial virus infection among the children under 60 months of age with lower respiratory tract infections in the capital area, the Republic of Korea, 2008-2011. J Korean Soc Neonatol 2012;19:195-203. 

    상세보기

저자의 다른 논문 :

강수영 (2)